Artelo Biosciences (ARTL) Corporate presentation summary

Corporate highlights and strategy

• Advancing a platform of lipid signaling modulation drug candidates targeting pain, cancer, anxiety, depression, and other conditions.

• Portfolio includes novel science, robust patent estate, and experienced leadership.

• Focused on billion-dollar markets with near-term catalysts expected.

Pipeline and clinical programs

• ART27.13: Dual cannabinoid receptor agonist in Phase 2 for cancer-related anorexia/cachexia and glaucoma.

• ART26.12: FABP5 inhibitor in Phase 1 for chemotherapy-induced peripheral neuropathy and various cancers.

• ART12.11: CBD:TMP cocrystal in late preclinical for anxiety and depression.

ART27.13 clinical data and potential

• Addresses cancer anorexia cachexia syndrome (CACS), affecting up to 80% of advanced cancer patients with no FDA-approved treatment.

• Demonstrated dose-dependent weight gain and increased activity in clinical studies.

• Well-tolerated with no dose-limiting toxicities or fatal adverse events in Phase 1 and 2.

• Phase 2 showed a 6% average weight increase at highest dose versus 5% decrease with placebo.